A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Last updated: May 7, 2025
Sponsor: Regeneron Pharmaceuticals
Overall Status: Active - Recruiting

Phase

1/2

Condition

Hemophilia

Treatment

REGV131

LNP1265

Clinical Study ID

NCT06379789
R131L1265-HEMB-2318
2023-507260-40-00
  • Ages > 18
  • Male

Study Summary

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.

The main aim of this study is to find a safe and well-tolerated dose of the study drug by checking the side effects that may happen from taking it.

The study is looking at several other research questions including:

  • How much study drug is in the blood at different times

  • Whether the body makes antibodies against parts of the study drug, which could make the drug less effective or could lead to side effects. Antibodies are proteins produced by the body's immune system in response to a foreign substance

  • Whether the body makes antibodies against the clotting factor replacement therapy

  • How quality of life is affected by hemophilia B and if it changes after taking study drug

  • How joint health is affected by hemophilia B and if it changes after taking study drug

  • How often visits are required for the emergency room, urgent care center, physician's office, hospital, telephone or online are required as a result of bleeding events, and if the frequency changes after taking study drug

  • How often factor replacement therapy is needed, both on a regular basis for prevention of bleeding, and as needed to treat bleeding events (and it if changes after taking study drug)

  • Whether there is a difference in 2 different methods for measuring Factor 9 activity in the blood

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. Confirmed diagnosis of severe or moderately severe hemophilia B with medical historyof FIX functional activity (≤2% or <0.02 IU/mL) or documented genotype known toproduce severe hemophilia B

  2. Currently taking FIX prophylaxis and previous experience with FIX therapy, asdefined in the protocol

  3. Participation in the lead-in period of this interventional study OR a separatelead-in study (R0000-HEMB-2187 [NCT05568459]) for at least 6 months for ABR datawhile taking FIX prophylaxis, as defined in the protocol

Exclusion

Key Exclusion Criteria:

  1. History of FIX inhibitor (clinical or laboratory-based assessment) on 2 or moreoccasions

  2. Bethesda inhibitor titer greater than the upper limit of normal (ULN) at screening

  3. Detectable pre-existing antibodies to the adeno-associated virus serotype 8 (AAV8)capsid; as measured by enzyme-linked immunosorbent assay (ELISA) at prescreening (orfinal lead-in visit, if applicable).

  4. Any significant underlying liver disease such as: cholestatic liver disease, livercirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy

  5. Evidence of advanced liver fibrosis, as defined in the protocol

  6. Evidence of cirrhosis and/or portal hypertension as assessed by abdominal ultrasoundat screening or measured within 6 months prior to the screening visit

  7. History of arterial or venous thrombo-embolic events, as defined in the protocol

  8. History of hypersensitivity to corticosteroids or known medical condition thatrequires chronic administration of corticosteroids

  9. Previously received any AAV gene-based therapy or intends to receive approved orinvestigational AAV-based gene therapy other than REGV131-LNP1265 during the studyperiod

NOTE: Other Inclusion/Exclusion Protocol Defined Criteria Apply

Study Design

Total Participants: 130
Treatment Group(s): 2
Primary Treatment: REGV131
Phase: 1/2
Study Start date:
September 11, 2024
Estimated Completion Date:
December 17, 2032

Study Description

The study will be conducted with a 2-part adaptive design, with enrollment of patients into sequential parts of the study.

Part 1: Dose Escalation and Dose Confirmation in adult patients ≥18 years of age

  • Dose Escalation Cohorts to determine the recommended dose for expansion (RDE) of REGV131-LNP1265

  • Dose Confirmation Cohort to gain further confidence in safety, tolerability, and Coagulation Factor IX (FIX) functional activity data at the RDE

Part 2: Dose Expansion at the RDE

  • Part 2A: Adult patients ≥18 years of age: RDE of REGV131-LNP1265, as determined in Part 1

  • Part 2B: Adolescent patients <18 and ≥12 years of age will be administered weight-adjusted RDE

  • Part 2C: Adolescent and Pediatric patients ≥2 to <12 years may be enrolled in an age staggered sequential manner; first participants aged ≥6 to <12 years and then participants ≥2 to <6 years of age and will receive a weight-adjusted RDE

Connect with a study center

  • McMaster University Medical Centre - Hamilton Health Sciences

    Hamilton, Ontario L8N 3Z5
    Canada

    Active - Recruiting

  • Orthopaedic Hemophilia Treatment Center

    Los Angeles, California 90007
    United States

    Active - Recruiting

  • University of California Davis

    Sacramento, California 95817
    United States

    Active - Recruiting

  • University California San Francisco

    San Francisco, California 94143
    United States

    Active - Recruiting

  • Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders

    New Orleans, Louisiana 70112
    United States

    Active - Recruiting

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.